Barclays’s Immune Design Corp. IMDZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-23,314
| Closed | -$136K | – | 7610 |
|
|
2019
Q1 | $136K | Buy |
23,314
+20,362
| +690% | +$69.4K | ﹤0.01% | 5113 |
|
|
2018
Q4 | $4K | Sell |
2,952
-11,047
| -79% | -$19.2K | ﹤0.01% | 6580 |
|
|
2018
Q3 | $49K | Buy |
13,999
+11,531
| +467% | +$43.3K | ﹤0.01% | 6101 |
|
|
2018
Q2 | $12K | Sell |
2,468
-4,217
| -63% | -$16.8K | ﹤0.01% | 6489 |
|
|
2018
Q1 | $22K | Buy |
6,685
+1,602
| +32% | +$5.67K | ﹤0.01% | 6404 |
|
|
2017
Q4 | $20K | Sell |
5,083
-7,213
| -59% | -$39.3K | ﹤0.01% | 6304 |
|
|
2017
Q3 | $127K | Buy |
12,296
+12,284
| +102,367% | +$121K | ﹤0.01% | 4769 |
|
|
2017
Q2 | $0 | Sell |
12
-534
| -98% | -$3.75K | ﹤0.01% | 7286 |
|
|
2017
Q1 | $3K | Sell |
546
-8,612
| -94% | -$49.8K | ﹤0.01% | 6439 |
|
|
2016
Q4 | $51K | Buy |
9,158
+8,988
| +5,287% | +$63.5K | ﹤0.01% | 5150 |
|
|
2016
Q3 | $1K | Sell |
170
-94
| -36% | -$687 | ﹤0.01% | 6563 |
|
|
2016
Q2 | $2K | Buy |
264
+196
| +288% | +$2.44K | ﹤0.01% | 6043 |
|
|
2016
Q1 | $1K | Sell |
68
-246
| -78% | -$2.84K | ﹤0.01% | 6093 |
|
|
2015
Q4 | $6K | Buy |
314
+254
| +423% | +$4.38K | ﹤0.01% | 5553 |
|
|
2015
Q3 | $1K | Sell |
60
-155
| -72% | -$2.9K | ﹤0.01% | 6781 |
|
|
2015
Q2 | $4K | Buy |
215
+32
| +17% | +$756 | ﹤0.01% | 6642 |
|
|
2015
Q1 | $4K | Sell |
183
-164
| -47% | -$4.28K | ﹤0.01% | 6752 |
|
|
2014
Q4 | $11K | Buy |
+347
| New | +$9.64K | ﹤0.01% | 6697 |
|
Barclays's IMDZ Position: Q2 2019 in Review
Barclays sold out of Immune Design Corp. (IMDZ) in Q2 2019, closing a stake of 23,314 shares — an estimated $136K sold.
Barclays first reported a position in IMDZ in Q4 2014 and held it in 18 quarters. The position peaked at $136K in Q1 2019. 0 funds tracked by Wall St. Rank hold IMDZ as of Q2 2019.
- Barclays reported no remaining Immune Design Corp. position as of Q2 2019 after selling out during the quarter.
- Barclays sold 23,314 Immune Design Corp. shares in Q2 2019, an estimated $136K.
- Barclays first reported a position in Immune Design Corp. in Q4 2014 and held it in 18 quarters.
- Barclays's Immune Design Corp. position peaked at $136K in Q1 2019.
- 0 funds tracked by Wall St. Rank held Immune Design Corp. as of Q2 2019.
Based on Barclays's 13F filing for Q2 2019, filed 14 Aug 2019.